Back to Journals » Risk Management and Healthcare Policy » Volume 12

Unlocking Access To Novel Medicines In China-A Review From A Health System Perspective

Authors Diao Y, Li M, Huang Z, Sun J, Chee YL, Liu Y

Received 7 August 2019

Accepted for publication 24 October 2019

Published 18 December 2019 Volume 2019:12 Pages 357—367

DOI https://doi.org/10.2147/RMHP.S226379

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Professor Marco Carotenuto


Yifan Diao,1 Mingshuang Li,1 Zhiran Huang,1 Jing Sun,1 Yoke Ling Chee,2 Yunali Liu1

1School of Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, People’s Republic of China; 2Third World Network, George Town 10400, Penang, Malaysia

Correspondence: Jing Sun; Yunali Liu
School of Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, 5 Dongdansantiao, Dongcheng District, Beijing 100730, People’s Republic of China
Tel/Fax +86-10-65105537
Email sunjing@sph.pumc.edu.cn; yliu@pumc.edu.cn

Abstract: China’s healthcare reform aims to provide affordable and equitable basic healthcare for all by 2020. Access to medicines is an essential part of the healthcare. The efforts of promoting access to medicines have been moving from meeting the needs of the basic healthcare, towards increasingly dedicated resources to offer breakthrough therapies. Looking at access to novel medicines from a health system perspective, and placing the changes China has made into that system context, this paper makes a comprehensive review of the progress of access to novel medicines in China. The review drew on two sources of information, which included desk review of published and grey literature, and key informant interview. Five hurdles were identified which create barriers of access to novel medicines, ranging from regulation and financing of medicines, intellectually property rights protection, and development of innovation capacity, to other health system components. Multiple policies have been implementing in China to remove the multiple access barriers gradually. Universal access to medicines has been moving from towards the basic common conditions to the world breakthrough technologies. We see cause for optimism, but recognize that there is a long way to go. Achieving broader and better access to modern medicines for Chinese patients will require multiple and coordinated government efforts, which would need to target the whole lifecycle regulation of novel medicines with a health system perspective, from balancing IP protection, strengthening R&D and public health, to appropriate regulatory approach and financing mechanism, and to supply chain management, as well as smart use.

Keywords: access to novel medicines, regulatory, affordability, IP, R&D, health system

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]